Terns Pharmaceuticals, Inc.
TERN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $108 | $0 | $0 |
| Gross Profit | $0 | -$108 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19,917 | $20,353 | $18,720 | $18,004 |
| G&A Expenses | $7,799 | $7,030 | $8,707 | $7,945 |
| SG&A Expenses | $7,799 | $7,030 | $8,707 | $7,945 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$108 | $0 | $0 |
| Operating Expenses | $27,716 | $27,275 | $27,427 | $25,949 |
| Operating Income | -$27,716 | -$27,383 | -$27,427 | -$25,949 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,127 | $3,354 | $3,607 | $4,190 |
| Pre-Tax Income | -$24,589 | -$24,029 | -$23,820 | -$21,759 |
| Tax Expense | $46 | $64 | $88 | $40 |
| Net Income | -$24,635 | -$24,093 | -$23,908 | -$21,799 |
| % Margin | – | – | – | – |
| EPS | -0.27 | -0.26 | -0.26 | -0.24 |
| % Growth | -3.8% | 0% | -8.3% | – |
| EPS Diluted | -0.27 | -0.26 | -0.26 | -0.24 |
| Weighted Avg Shares Out | 91,702 | 91,575 | 91,474 | 91,241 |
| Weighted Avg Shares Out Dil | 91,702 | 91,575 | 91,474 | 91,241 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,141 | $3,350 | $3,643 | $4,143 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $12 | $108 | $169 | $214 |
| EBITDA | -$24,577 | -$23,921 | -$27,258 | -$25,735 |
| % Margin | – | – | – | – |